Some authors also propose the use of neoadjuvant BRAF/MEK inhibitors in patients with neurological deficit, to benefit from the rapid tumour shrinkage [35].The timing of administration should be tailored to each patients’ characteristics. The gene discussed is MAP2K7; the disease is neoplasm.